Get the Stockscreener App
12.54
1.21%
0.15
After Hours:
12.50
-0.04
-0.32%
Oric Pharmaceuticals Inc stock is traded at $12.54, with a volume of 1.60M.
It is up +1.21% in the last 24 hours and up +50.72% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
See More
Previous Close:
$12.39
Open:
$12.67
24h Volume:
1.60M
Relative Volume:
2.92
Market Cap:
$884.91M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-6.9282
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
+16.43%
1M Performance:
+50.72%
6M Performance:
+39.49%
1Y Performance:
+1.95%
1-Day Range:
$12.36
$13.30
1-Week Range:
$9.95
$13.30
52-Week Range:
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.54 | 884.91M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
There is no doubt that ORIC Pharmaceuticals Inc (ORIC) ticks all the boxes. - SETE News
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - Knox Daily
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6%Still a Buy? - MarketBeat
Daily Market Movement: ORIC Pharmaceuticals Inc (ORIC) Sees a -2.59 Decrease, Closing at 10.15 - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC)’s stock chart: A technical perspective - US Post News
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data - Seeking Alpha
SG Americas Securities LLC Sells 3,256 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
JPMorgan Chase & Co. Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Three Major Healthcare Investor Conferences - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6%Should You Buy? - MarketBeat
Research Analysts Issue Forecasts for ORIC FY2025 Earnings - Defense World
Analysts Set Expectations for ORIC FY2025 Earnings - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8%Should You Sell? - MarketBeat
Q2 EPS Estimate for ORIC Pharmaceuticals Reduced by Analyst - Defense World
Q2 EPS Forecast for ORIC Pharmaceuticals Reduced by Analyst - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.29 - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Oric Pharmaceuticals announces clinical supply agreement with Janssen - Yahoo Finance
Barclays PLC Raises Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Buy Rating from HC Wainwright - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from Wedbush - Defense World
ORIC Pharmaceuticals advances cancer drug trials - Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from Wedbush - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpHere's What Happened - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
ORIC Pharmaceuticals, Inc. Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLCwith EGFR Exon 20 Insertion Mutations - Marketscreener.com
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations - The Manila Times
ORIC® Pharmaceuticals Provides Early Phase 1b Combination - GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Supply Agreement to - GlobeNewswire
ORIC Pharma's Cancer Drug Shows Strong Early Results, Partners With J&J for Lung Cancer Trial - StockTitan
ORIC Partners with Janssen to Test ORIC-114 Combo Therapy for First-Line NSCLC Treatment - StockTitan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 8.8%Here's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Jane Street Group LLC - Defense World
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Awards Inducement Grants to New Employee, Including Stock Options - StockTitan
Geode Capital Management LLC Boosts Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Barclays PLC Has $1.10 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Trading Signals - Stock Traders Daily
EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma - The Globe and Mail
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownHere's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.4%Should You Sell? - MarketBeat
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):